• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical and Diagnostic Research >Linezolid and Vancomycin Resistant Enterococci: A Therapeutic Problem GC07-GC11
【24h】

Linezolid and Vancomycin Resistant Enterococci: A Therapeutic Problem GC07-GC11

机译：耐利奈唑胺和万古霉素的肠球菌：一个治疗问题GC07-GC11

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Enterococci are recognized as opportunistic pathogens, as well as commensals in both humans and animals. They are an important cause of nosocomial infections, difficult to treat, as the organism have intrinsic and acquired resistance to many antibiotics.Aim: To isolate and identify clinically relevant Enterococcus up to species level from all the clinical samples processed in the microbiology laboratory and also to study their resistance pattern.Materials and Methods: A prospective study was carried out for a period of one year from May 2014 to April 2015 at the Department of Microbiology, Subharti Medical College, Meerut, Uttar Pradesh, India. A total of 200 isolates of Enterococcus species from 15342 clinical samples obtained from IPD/OPD patients irrespective of age, having suspicion of bacterial infection were processed in the microbiology laboratory. Identification was done with standard biochemical methods. Antibiotic susceptibility testing was done on Muller Hilton agar plate by Kirby Bauer disc diffusion method. High-Level Gentamycin Resistance (HLGR) and High-Level Streptomycin Resistance (HLSR) were further confirmed by Agar dilution method and Broth microdilution method. Vancomycin and linezolid resistance was further confirmed by Agar dilution method and MIC was calculated by using VITEK 2, Biomerieux. All methodology was followed as per Clinical and Laboratory Standards Institute (CLSI) M100-S 24, 2014 guidelines.Results: E. faecalis (n=169, 84.5%) was the predominant species isolated, followed by E. faecium (n=27, 13.5%) and E. casseliflavus (n=4, 2%). A total of 25 (12.5%) isolates were HLGR, 13 (6.5%) isolates were HLSR and 62 (31%) isolates were HLGR+HLSR. Vancomycin resistance was found in 14 (7%) isolates of which 11 (78.5%) were Van A and 3 (21.4%) were Van B, detected phenotypically as per relative MIC of vancomycin and teicoplanin. Linezolid resistance was seen in 4 (2%) of isolates which were vancomycin as well as high-level gentamycin and high-level streptomycin resistant.Conclusion: Isolation of Enterococcus species resistant to most of the higher antibiotics like vancomycin and linezolid, with high prevalence of High-Level Aminoglycoside Resistance (HLAR), from hospitalized patients is a major concern as such isolates have limited or no therapeutic option.
机译：简介：肠球菌是公认的机会性病原体，在人类和动物中都具有共鸣作用。它们是导致医院感染的重要原因，难以治疗，因为该生物体对多种抗生素具有内在的和获得性的耐药性。目的：从微生物实验室处理的所有临床样品中分离并鉴定直至物种水平的临床相关肠球菌。材料和方法：前瞻性研究从2014年5月至2015年4月在印度北方邦密拉特市Subharti医学院微生物系进行了为期一年的研究。在微生物实验室中处理了从15342份IPD / OPD患者的临床样本中分离出的共200株肠球菌，这些样本不分年龄，怀疑细菌感染。鉴定采用标准生化方法进行。抗生素敏感性试验是通过Kirby Bauer圆盘扩散法在Muller Hilton琼脂平板上进行的。琼脂稀释法和肉汤微量稀释法进一步证实了高庆大霉素抗性（HLGR）和高链霉素抗性（HLSR）。通过琼脂稀释法进一步证实了对万古霉素和利奈唑胺的耐药性，并使用Biomerieux VITEK 2计算MIC。所有方法均遵循临床和实验室标准协会（CLSI）M100-S 24，2014指南进行操作。结果：粪肠球菌（n = 169，84.5％）是分离的主要菌种，其次是粪肠球菌（n = 27） ，13.5％）和卡塞夫拉夫斯大肠杆菌（n = 4，2％）。 HLGR共有25（12.5％）株，HLSR共有13（6.5％）株，HLGR + HLSR共有62（31％）株。根据万古霉素和替考拉宁的相对MIC，从表型上检测出14株（7％）分离株对万古霉素的耐药性，其中11株（78.5％）为Van A，3株（21.4％）为VanB。对万古霉素，高庆大霉素和高链霉素耐药的分离株中有4（2％）株对利奈唑胺耐药。住院患者对高水平氨基糖苷耐药性（HLAR）的研究是一个主要问题，因为此类分离物的治疗选择有限或没有治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号